{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:44:44Z","timestamp":1764996284403,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Cancer Center Core"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA 21765"],"award-info":[{"award-number":["P30 CA 21765"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Posaconazole exhibits broad-spectrum antifungal activity. An IV formulation became available in 2014. Few studies describing the use of this formulation exist in patients under the age of 18\u2009years. This study describes our experience using IV posaconazole in paediatric and young adult cancer patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single-centre retrospective chart review evaluated patients who received IV posaconazole and had at least one posaconazole plasma concentration obtained after five or more days with a consistent dosage. Relationships between doses required to achieve a plasma concentration of \u22651\u2009\u00b5g\/mL and patient age, weight and body surface area (BSA) were evaluated. The clinical record was reviewed to identify descriptions of any adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-five patients were analysed, with a median age of 10.5\u2009years (range 1.9\u201322.9\u2009years; 92% were &amp;lt;18\u2009years). All patients were able to achieve a posaconazole plasma concentration \u22651\u2009\u00b5g\/mL during their treatment course. The daily mg\/kg\/day dose required to achieve the target concentration decreased significantly with increasing age of the patient (P\u2009=\u20090.018). Assessment of dosage based on BSA suggested a requirement of 225\u2009mg\/m2\/day across all age groups &amp;lt;18\u2009years. Adverse events documented in the clinical record were consistent with those described with the oral formulations. No CNS toxicities were observed with use of IV posaconazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Concentrations \u22651\u2009\u00b5g\/mL are achievable and a BSA-based dosing approach may allow a consistent empirical dose for patients &amp;lt;18\u2009years of age. Therapeutic drug monitoring is recommended to ensure patients achieve therapeutic concentrations.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkaa377","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T03:24:56Z","timestamp":1597375496000},"page":"3682-3687","source":"Crossref","is-referenced-by-count":7,"title":["Experience using intravenous posaconazole in paediatric and young adult oncology patients"],"prefix":"10.1093","volume":"75","author":[{"given":"Arathi A","family":"Lambrix","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Primary Children\u2019s Hospital, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope D","family":"Swanson","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L","family":"Pauley","sequence":"additional","affiliation":[{"name":"Department of Global Pediatric Medicine, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison W","family":"Bragg","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delia C","family":"Carias","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa S","family":"Bourque","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinmei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L","family":"Greene","sequence":"additional","affiliation":[{"name":"Pharmaceutical Department, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Maron","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"2020111305161829000_dkaa377-B1","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"year":"2014","key":"2020111305161829000_dkaa377-B2"},{"key":"2020111305161829000_dkaa377-B3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111305161829000_dkaa377-B4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/11592630-000000000-00000","article-title":"Effect of pH and comedication on gastrointestinal absorption of posaconazole","volume":"50","author":"Walravens","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2020111305161829000_dkaa377-B5","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1128\/AAC.00889-09","article-title":"Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111305161829000_dkaa377-B6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/IDR.S65592","article-title":"Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole","volume":"8","author":"Soysal","year":"2015","journal-title":"Infect Drug Resist"},{"key":"2020111305161829000_dkaa377-B7","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111305161829000_dkaa377-B8","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020111305161829000_dkaa377-B9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.vascn.2015.07.011","article-title":"Magnetic resonance imaging assessment of the ventricular system in the brains of adult and juvenile beagle dogs treated with posaconazole IV solution","volume":"76","author":"Hines","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2020111305161829000_dkaa377-B10","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.bbmt.2016.12.150","article-title":"Intravenous posaconazole is safe and effective in pediatric HSCT patients","volume":"23","author":"Teusink-Cross","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020111305161829000_dkaa377-B11","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1093\/ofid\/ofx163.681","article-title":"Safety, tolerability and pharmacokinetics (PK) of posaconazole (POS) intravenous (IV) solution and oral powder for suspension in children with neutropenia","volume":"4","author":"Groll","year":"2017","journal-title":"OFID"},{"key":"2020111305161829000_dkaa377-B12","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/MPH.0000000000001071","article-title":"Use of intravenous posaconazole in hematopoietic stem cell transplant patients","volume":"40","author":"Strommen","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"2020111305161829000_dkaa377-B13","first-page":"528","article-title":"Intravenous and oral posaconazole pharmacokinetics in a five-year-old with Mucor: a case report and review of the literature","volume":"24","author":"Ruland","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2020111305161829000_dkaa377-B14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jpids\/piy094","article-title":"Evaluation of intravenous posaconazole dosing and pharmacokinetic target attainment in pediatric patients","volume":"8","author":"Nickless","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"author":"Groll","key":"2020111305161829000_dkaa377-B15"},{"key":"2020111305161829000_dkaa377-B16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1345\/aph.1R775","article-title":"Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer","volume":"47","author":"Bernardo","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2020111305161829000_dkaa377-B17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure\u2013response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"2020111305161829000_dkaa377-B18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimizing antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"2020111305161829000_dkaa377-B19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group","volume":"46","author":"Paul","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020111305161829000_dkaa377-B20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.14.53","article-title":"Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes","volume":"15","author":"Hicks","year":"2014","journal-title":"Pharmacogenomics"},{"key":"2020111305161829000_dkaa377-B21","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020111305161829000_dkaa377-B22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1542\/peds.5.5.783","article-title":"Simplification of drug dosage calculation by application of the surface area principle","volume":"5","author":"Crawford","year":"1950","journal-title":"Pediatrics"},{"key":"2020111305161829000_dkaa377-B23","first-page":"853","article-title":"The use of body surface area as a criterion of drug dosage in cancer chemotherapy","volume":"18","author":"Pinkel","year":"1958","journal-title":"Cancer Res"},{"key":"2020111305161829000_dkaa377-B24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/INF.0000000000000963","article-title":"Pharmacokinetics of posaconazole oral suspension in children dosed according to body surface area","volume":"35","author":"Vanstraelen","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2020111305161829000_dkaa377-B25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.00454-06","article-title":"Posaconazole plasma concentrations in juvenile patients with invasive fungal infection","volume":"51","author":"Krishna","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020111305161829000_dkaa377-B26","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1128\/AAC.00062-11","article-title":"Relevance of timing for determination of posaconazole plasma concentrations","volume":"55","author":"Heinz","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3682\/34291530\/dkaa377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3682\/34291530\/dkaa377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T22:22:05Z","timestamp":1667773325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/12\/3682\/5905596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,14]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa377","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,14]]}}}